Carcinine

Other Names

3-Amino-N-[2-(1H-imidazol-4-yl)ethyl]propanamide3-Amino-N-[2-(1H-imidazol-4-yl)ethyl]propionamide3-Amino-N-[2-(1H-imidazol-5-yl)ethyl]propanamide3-Amino-N-[2-(3H-imidazol-4-yl)ethyl]propanamide3-Amino-N-[2-(3H-imidazol-4-yl)ethyl]propionamideAlistinbeta-alaninylhistaminebeta-AlanylhistamineDecarboxy carnosineDecarboxycarnosineDecarboxylated carnosineDecarboxylation carnosineN-(2-(1H-Imidazol-5-yl)ethyl)-3-aminopropanamideN-(β-Alanyl)histamineN-[2-(1H-imidazol-4-yl)ethyl]-β-alaninamideN-[2-(1H-imidazol-5-yl)ethyl]-β-alaninamidePropanamide, 3-amino-N-[2-(1H-imidazol-4-yl)ethyl]-Propanamide, 3-amino-N-[2-(1H-imidazol-5-yl)ethyl]-β-Alaninylhistamineβ-Alanylhistamine

Synopsis

Carcinine (β-Alanyl-Histamine): A Comprehensive Reference

1. Identity, Chemical Characterization, and Natural Sources

Chemical Identity

Carcinine is a natural imidazole-containing peptide derivative formally known as β-alanyl-histamine (also rendered as β-alanylhistamine). It is a monocarboxylic acid amide and a member of the imidazole class of compounds, derived from histamine. Its molecular formula is C₈H₁₄N₄O, and it appears in chemical databases under PubChem CID 2574. As a natural peptide derivative, it contains a β-alanyl residue and a histamine moiety, and carries an imidazole ring.

Carcinine is a close structural analogue of the well-studied dipeptide carnosine (β-alanyl-L-histidine). In the carnosine family of compounds, carcinine is the variant in which L-histidine is replaced by histamine — that is, the amino group of histidine is decarboxylated to produce histamine before conjugation with β-alanine.

Synonyms and Registry Numbers

The compound is known in the literature under several names and identifiers: β-alanylhistamine, β-alanyl-histamine, carcinine dihydrochloride (the salt form commonly used in laboratory studies), and the IUPAC name N-(4-imidazolylethyl)-β-alaninamide. CAS numbers cited in research literature include 57022-38-5 and 56897-53-1 (for the free base and hydrochloride salt, respectively).

Natural Sources and Biological Distribution

Carcinine was first identified in crustaceans and the hearts of mammals. Specifically, carcinine was originally characterized in the crab Carcinus maenas. Carcinine was biosynthesized by Carcinus maenas from ¹⁴C-labeled β-alanine, histidine, and histamine; and since carnosine could not be detected in crab tissues, biosynthesis of carcinine could only proceed by direct coupling of β-alanine and histamine resulting from histidine decarboxylation.

In mammals, carcinine is present in the brain, muscle, intestine, and liver tissues. Carnosine and carcinine are natural imidazole-containing compounds found in the non-protein fraction of mammalian tissues. Carcinine has been identified in several tissues of the rat, guinea pig, mouse, and human.

In Drosophila melanogaster, carcinine plays a critical functional role: flies recycle the photoreceptor neurotransmitter histamine by conjugating it to β-alanine to form β-alanyl-histamine (carcinine). The conjugation is regulated by the enzyme Ebony, while Tan hydrolyses carcinine, releasing histamine and β-alanine.

Common Forms and Preparations

Carcinine is used and studied in several forms:

Carcinine free base — used in biochemical assays and some in vivo studies.
Carcinine dihydrochloride — the salt form used in most pharmacological experiments and available as a research-grade reagent from suppliers such as Sigma-Aldrich.
Oral supplement capsules — marketed in patented stabilized formulations (e.g., the tradename Glycoless®). Glycoless® is described as a patented form of carcinine, attracting scientific interest due to its effects on protein glycation.
Topical / ophthalmic preparations — investigated in conjunction with N-acetylcarnosine eye drops for ophthalmic indications.
Biotechnologically produced carcinine — a whole-cell transformation system converting β-alanine and histamine to carcinine by the enzymes Ebony and phosphopantetheine transferase (Sfp) has been developed, addressing high production costs that have previously limited broad application.

2. Discovery and Historical Context

Carcinine does not share the centuries-long ethnobotanical or folk-medicine history of many plant-derived supplements. Its story is one of modern biochemical discovery rather than traditional use. It was first identified in crustaceans and the hearts of mammals (Arnould and Frentz, 1975). This initial discovery in the crab Carcinus maenas is reflected in the compound's name.

The early biochemical literature traced carcinine's biosynthetic origin in Carcinus maenas through radio-isotopic labeling experiments. After injecting ¹⁴C-histamine into Carcinus, radioactive carcinine was concentrated mainly in the heart and nervous system, indicating that carcinine is a product of histamine catabolism. A dedicated biosynthetic enzyme was subsequently characterized: carcinine biosynthesis was induced in vitro from β-alanine and histamine, and the reaction was catalyzed by muscle, heart, and CNS extracts from Carcinus maenas. The specific activity of the enzyme, carcinine synthetase, was 15 times higher in CNS than in other organs.

Carcinine was subsequently identified in several tissues of the rat, guinea pig, mouse, and human, and was then shown to be metabolically related in vivo to histamine, histidine, carnosine, and 3-methylhistamine through radioisotopic labeling. These findings suggested a role for carcinine in the carnosine-histidine-histamine metabolic pathway and in the mammalian physiologic response to stress.

Interest in carcinine as a potential bioactive supplement and pharmaceutical agent emerged in the 1990s and 2000s, largely through the work of researchers exploring the carnosine family of compounds for antioxidant, anti-glycation, and neuroprotective applications. The compound has not been the subject of traditional-medicine use in any documented cultural tradition; references to historical use of "carnosine-related compounds" in Eastern European and Asian folk medicine concern carnosine itself (found abundantly in meat), not carcinine specifically.

3. Biosynthesis and Biochemical Relationship to Carnosine and Histamine

Carcinine occupies a nexus among three important bioactive molecules — β-alanine, histamine, and carnosine — making its metabolism of broad biological interest.

In vivo biosynthesis of carcinine is closely related to histamine, histidine, and carnosine metabolism. It can be synthesized in vitro from histamine and β-alanine (β-Ala) by Arnould's synthesis.

In Drosophila, the enzymatic machinery governing carcinine turnover is well characterized: the biosynthesis of carcinine has been studied in Drosophila melanogaster, where the reaction of β-alanine and histamine to carcinine is catalyzed by the enzyme Ebony. Ebony is an important nonribosomal peptide synthetase (NRPS), which mainly occurs in glial and cuticular cells. Histamine and dopamine are metabolized by N-β-alanyl-dopamine synthetase (Ebony) into their β-alanyl derivatives, carcinine and N-β-alanyl-dopamine, respectively. The conjugation is regulated by Ebony, while Tan hydrolyses carcinine, releasing histamine and β-alanine.

Ebony activates β-alanine to aminoacyladenylate by an adenylation domain and covalently attaches it as a thioester to a thiolation domain in a nonribosomal peptide synthetase (NRPS)-related mechanism. In a second reaction, biogenic amines act as external nucleophiles on β-alanyl-S-pantetheine-Ebony, releasing the dipeptide in a fast reaction that is novel in higher eukaryotes. Ebony is thus defined as a β-alanyl-biogenic amine synthetase.

In mammals, the analogous Ebony/Tan orthologues are absent: there are no proteins related in sequence to Tan and Ebony in any vertebrate genome sequenced to date. In mammalian tissues, carcinine is nonetheless present as a minor metabolite and is produced through related but less well-characterized enzymatic routes that intersect with the general histamine metabolic pathway.

4. Key Active Compounds and Mechanisms of Action

Carcinine's pharmacological profile arises from several distinct but overlapping mechanisms.

4.1 Antioxidant Activity: Hydroxyl Radical Scavenging and Lipid Peroxidase Activity

Carnosine and carcinine are natural imidazole-containing compounds found in the non-protein fraction of mammalian tissues. Both carnosine and carcinine (at 10–25 mM) were shown to efficiently reduce and deactivate lipid hydroperoxides (including 13-monohydroperoxide linoleic acid and phosphatidylcholine hydroperoxide) in liberated and bilayer-bound states. Due to the combination of weak metal chelating, hydroxyl radical scavenging, and reducing activity toward liberated fatty acid and phospholipid hydroperoxides, carnosine and carcinine appear to be physiological antioxidants able to efficiently protect the lipid phase of biological membranes and aqueous environments.

Notably, imidazole alone, solutions of β-alanine, or their mixtures with peptide moieties did not show antioxidant potential; whereas free L-histidine and especially histamine actually stimulated iron(II) salt-dependent lipid peroxidation. This establishes that the intact dipeptide structure of carcinine is required for antioxidant activity, and that it does not simply act as a source of free histamine.

4.2 Scavenging of 4-Hydroxynonenal (4-HNE)

Carcinine can scavenge 4-hydroxynonenal (4-HNE), a toxic product obtained during lipid oxidation. The ability of carcinine to form an adduct with 4-HNE, as well as to prevent and even reverse the adduction of retinal proteins by this toxic aldehyde, was demonstrated in vitro. This quenching activity prevents and even reverses detrimental 4-HNE modification of retinal proteins. Systemic administration of carcinine led to its accumulation in the retina and to a strong neuroprotection of photoreceptor cells against light-induced oxidative damage.

4.3 Anti-Glycation and Glycation-Reversal Activity

Carcinine, as a member of the carnosine family of modified compounds (including anserine and homocarnosine), shows a similar ability to inhibit advanced glycation end-product (AGE) formation, in part through activity in the stabilization of Schiff bases derived from carnosine and 1,2-dicarbonyl compounds.

Carnosine and carcinine exhibit well-documented anti-glycating activity against the glycation of proteins, including low-density lipoproteins and glucose-modified proteins. Research has revealed that these endogenous imidazole-containing dipeptide compounds are present in surprisingly large amounts in long-lived human tissues and can correct conformational abnormalities linked to neurodegeneration and age-related disease.

The transglycating activity, inhibition of transition metal ion peroxidative catalysts, resistance to hydrolysis with carnosinase, and the protective effects of carnosine, carcinine, and related compounds against the oxidative damage of proteins and lipid membranes have been assessed in a number of biochemical and model systems.

4.4 Histamine H3 Receptor Antagonism

Carcinine (β-alanyl-histamine) is a selective histamine H3 antagonist, 100–1000-fold selective for H3 over H2 and H1, that also functions as an antioxidant and as a chemical chaperone to reduce non-enzymatic glycation of proteins and maintain native protein folding.

The study by Chen et al. (2004) published in the British Journal of Pharmacology provides direct evidence that carcinine is a new histamine H3 receptor antagonist. Carcinine at a dose of 20 mg/kg slightly increased histidine decarboxylase (HDC) activity in the cortex. In addition, carcinine (10, 20, and 50 mg/kg) significantly decreased histamine levels in mice brain. Like thioperamide (a reference H3 antagonist), carcinine (20, 50 μM) significantly increased 5-HT release from mice cortex slices, but had no apparent effect on dopamine release.

4.5 Chemical Chaperone Function

Carcinine also functions as a chemical chaperone to reduce non-enzymatic glycation of proteins and maintain native folding of proteins. Carcinine was found to have positive effects on human skin in terms of antioxidant and anti-aging effects as well as anti-glycation and glycation reversal.

4.6 Superoxide Dismutase (SOD) Protection

Research found that carcinine can protect the skin by reducing the oxidative deactivation of superoxide dismutase (SOD) in cutaneous cells during UV irradiation by 43%.

4.7 Positive Inotropic Effect at the Heart

Carcinine is a minor metabolite in mammals, in which it exerts a positive inotropic action at the heart. This cardiac effect was documented early in the literature on carcinine's physiological roles and distinguishes it metabolically from carnosine, which does not share this property to the same degree.

5. Scientific Evidence by Area of Use

5.1 Retinal and Ophthalmic Neuroprotection

The retina-related research on carcinine is among the most developed area of preclinical investigation.

Oxidative stress and lipid peroxidation induce retinal damage and contribute to vision loss in progressive retinopathies such as age-related macular degeneration (AMD), diabetic retinopathy, and retinitis pigmentosa. Carcinine is a naturally occurring imidazole-containing pseudopeptide with known antioxidant activity. It is also predicted to have a quenching effect on 4-hydroxynonenal (4-HNE), a highly toxic product of oxidative stress.

A key study published in Investigative Ophthalmology & Visual Science (2012) by Marchette et al. directly tested these properties: the study confirmed the 4-HNE scavenging effect and evaluated the neuroprotective effect of carcinine in mouse retina subjected to oxidative stress, using HPLC coupled with mass spectrometry to analyze carcinine and 4-HNE-carcinine adducts. The ability of carcinine to form an adduct with 4-HNE, as well as to prevent and even reverse the adduction of retinal proteins by the toxic aldehyde, was demonstrated in vitro. Carcinine, administered by intravitreal injection or gavage, strongly protected mouse retina against light-induced photoreceptor degeneration and had a protective effect on RHD12, a protein found specifically in photoreceptor cells. The study suggests that carcinine can be administered noninvasively to efficiently protect photoreceptor cells from oxidative damage.

However, the amount of carcinine found within the retina after systemic administration was limited, suggesting poor transportation through the blood-retinal barrier, rapid degradation of carcinine within the retina, and/or rapid reaction with other molecules. Although the amount of carcinine within the retina was low, it protected retinal structure and function from light-induced retinal degeneration.

Compounds with antioxidant properties neutralize reactive oxygen species before they can induce any damage, providing a first line of defense against free radicals. With combined antioxidant and 4-HNE quenching activities, carcinine offers a second line of defense by targeting secondary products of oxidative stress. This combined activity was shown to be beneficial in protecting photoreceptor cells from oxidative damage.

Evidence strength: This evidence is based entirely on in vitro biochemical assays and animal (mouse) models. No human clinical trials have investigated carcinine specifically for retinal protection. The evidence is preliminary and preclinical only.

5.2 Neurological Effects: Histaminergic Activation, Cognition, and Epilepsy Models

The 2004 study by Chen et al. in British Journal of Pharmacology is the primary pharmacological characterization of carcinine's CNS effects: the results of this study provide first and direct evidence that carcinine, as a novel histamine H3 receptor antagonist, plays an important role in histaminergic neuron activation and might be useful in the treatment of certain diseases, such as epilepsy, and locomotor or cognitive deficit.

Specific behavioral findings in rodent models included: like thioperamide (a histamine H3 receptor antagonist), carcinine (20 and 50 μM) significantly increased 5-HT release from mice cortex slices, but had no apparent effect on dopamine release. Carcinine (20 mg/kg) significantly inhibited pentylenetetrazole-induced kindling. This inhibition was completely reversed by (R)-α-methylhistamine, a representative H3 receptor agonist, and α-fluoromethylhistidine, a selective HDC inhibitor. Carcinine (20 mg/kg) ameliorated the learning deficit induced by scopolamine, as evaluated by the passive avoidance test in mice. Like thioperamide, carcinine dose-dependently increased mice locomotor activity in the open-field test.

Carcinine is identified as a novel histamine H3 receptor antagonist, significantly decreasing histamine levels in the cortex and midbrain by up to 44.6% at 20 mg/kg administered 60 minutes post-administration.

Histamine H3 receptors exist as heteroreceptors, present not only in the histaminergic nerve terminals in the brain but also in the terminals of other neurotransmitter systems. Several reports have demonstrated functional interactions between histaminergic, serotoninergic, and dopaminergic neurotransmission. Carcinine's H3 antagonism therefore implies potential influence over multiple neurotransmitter systems simultaneously.

Evidence strength: All neurological evidence is from animal (rodent) models and in vitro cell preparations. No human trials on carcinine for neurological conditions have been published as of the available literature. Evidence is preclinical only.

5.3 Metabolic Syndrome, Glycaemia, and Lipid Profile

One observational, retrospective human trial has reported results with carcinine supplementation for metabolic parameters. The objective was to study the active role of carcinine, an L-carnosine metabolite, in insulin resistance and dyslipidaemia, and to modulate the insulinemic/glycaemic profile and fat metabolism. One hundred volunteers (50 women and 50 men), aged 40–85 years with a BMI of 25–34.9 kg/m², were included in this anecdotal, observational, retrospective trial. After 60 mg/day of carcinine treatment, glycaemia (p=0.001), glycated haemoglobin (p<0.001), total cholesterol (p<0.003), and serum insulin (p<0.05) were significantly reduced, compared to placebo period. Abdominal circumference (p<0.2) and HOMA index (p<0.03) were progressively reduced as well. No cardiovascular risk or adverse effects were observed at the prescribed dosages. The AGE reader test showed a statistically meaningful reduced risk due to reduced AGE accumulation. The authors concluded that carcinine, at a daily dose of 60 mg/day, was able to modify, safely, AGE-induced cardiovascular risk, waist circumference, and glycolipid-metabolic parameters in overweight/obese patients with altered blood glucose patterns.

Evidence strength: This is the only published human trial specifically on carcinine. It is described by its authors as "anecdotal, observational, retrospective," which represents a low level of evidence. The trial was not a prospective, randomized controlled trial (RCT) and therefore cannot establish causality. It serves as a hypothesis-generating finding requiring confirmation in rigorous controlled trials.

5.4 Skin Aging, Photoprotection, and Anti-Glycation in Skin

Carcinine was found to have positive effects on human skin in terms of antioxidant and anti-aging effects as well as anti-glycation and glycation reversal. Skin beautification with oral non-hydrolyzed versions of carnosine and carcinine has been explored as effective therapeutic management and cosmetic skincare solutions against oxidative glycation and free-radical production as a causal mechanism of diabetic complications and skin aging.

Under aerobic conditions, molecular oxygen can accept an electron from the methylglyoxal anion to generate the superoxide radical anion, causing propagation of oxidative stress chain reactions in the presence of transition metal ions. Carnosine, when stabilized from enzymatic hydrolysis, carcinine, and leucyl-histidylhydrazide in patented formulations demonstrate Schiff base transglycating activities concomitant with glycation site-specific antioxidant activities.

A working therapeutic concept from Babizhayev's group proposes that imidazole-containing dipeptide-based compounds (non-hydrolyzed carnosine and carcinine) can modulate telomerase activity in normal cells and can provide redox regulation of cellular function under conditions of environmental and oxidative stress, thereby protecting telomere length and structure from attrition.

Evidence strength: Much of this evidence originates from biochemical model systems, cell culture, and animal models, together with theoretical and review-level publications, often by the same research group (Babizhayev and colleagues). Rigorously controlled, independently replicated human trials on carcinine's skin effects are lacking in the peer-reviewed literature.

5.5 Potential Anti-Tumor Activity

Carcinine is used in the cosmetics industry as an anti-aging supplement with antioxidant, anti-glycation, and glycation reversal functions, and has a notable pharmacological effect as an anti-tumor drug and in protection against retinopathy. However, this statement from a biotechnology paper refers to the compound's purported research uses without citing specific controlled clinical evidence. No peer-reviewed human trials on carcinine's anti-tumor activity could be identified in the primary literature search.

Evidence strength: Any anti-tumor activity of carcinine remains uncharacterized by controlled human evidence and is at best a theoretical area of investigation based on its antioxidant and anti-glycation properties.

5.6 Cardiovascular Effects

Early studies on vertebrate blood pressure demonstrated that carcinine had no influence on heartbeat frequency or respiratory movements in rats. It had a vasodepressive action upon vertebrates. It was active at half the concentration of carnosine and at about a thousand times the concentration of histamine. It appeared that histamine lost a great extent of its activity when linked with β-alanine.

In mammals, carcinine also exerts a positive inotropic action at the heart.

Evidence strength: These findings are from early animal experiments. No human cardiovascular studies on carcinine have been published.

6. Body Systems and Health Areas Associated with Carcinine

Visual system / retina: Investigated for protection of photoreceptor cells from oxidative and lipid peroxidation damage, with potential relevance to AMD, diabetic retinopathy, and retinitis pigmentosa (animal data only).
Central nervous system: H3 receptor antagonism, modulation of histaminergic, serotoninergic tone; exploratory rodent models of epilepsy, cognitive deficit, and locomotor activity.
Metabolic system: Reduction of blood glucose, glycated hemoglobin, cholesterol, and insulin resistance (one low-level human observational study at 60 mg/day).
Skin / integumentary system: Anti-glycation, anti-AGE, anti-oxidant effects on collagen and skin proteins; UV photodamage protection (biochemical and cell culture evidence).
Cardiovascular system: Positive inotropic effects (animal data); vasodepressive action (early vertebrate studies).
General cellular aging: Inhibition of AGE formation, metal chelation, hydroxyl radical scavenging, and possible telomerase modulation (biochemical/theoretical evidence).

7. Dosage Forms and Dosages Reported in Studies

Reported doses vary considerably between preclinical and the one available human study, and should be interpreted strictly in the context of the study reporting them:

60 mg/day (oral, human): Carcinine, at the daily dose of 60 mg/day, was able to modify, safely, AGEs that induced cardiovascular risk, the waist circumference, and glycolipid-metabolic parameters in overweight/obese patients with altered blood glucose patterns. This is the only documented dose in a human study.
10, 20, and 50 mg/kg (intraperitoneal, rodent): Carcinine at a dose of 20 mg/kg slightly increased HDC activity in the cortex. In addition, carcinine (10, 20, and 50 mg/kg) significantly decreased histamine levels in mice brain.
20, 50 μM (in vitro, cortex slices): Carcinine (20 and 50 μM) significantly increased 5-HT release from mice cortex slices.
0.5 mM (in vitro, retinal protein incubation): Carcinine (0.5 mM) was incubated to form an adduct with 4-HNE in vitro.
Intravitreal injection and gavage (mouse retina study): Carcinine, administered by intravitreal injection or gavage, strongly protected mouse retina against light-induced photoreceptor degeneration. Specific mg/kg doses for this route were not stated in the available abstracts.
10–25 mM (in vitro antioxidant assays): Both carnosine and carcinine (10–25 mM) efficiently reduced and deactivated lipid hydroperoxides in liberated and bilayer-bound states.

8. Safety Considerations and Known Interactions

8.1 Human Safety Data

No cardiovascular risk and no untoward effects were observed at the prescribed dosages (60 mg/day) in the single published human observational study. Carcinine is described as a well-tolerated natural product which could easily be used in chronic treatment to slow down vision loss in progressive retinopathies, based on preclinical findings — but this conclusion has not yet been tested in formal human safety or tolerability studies.

Formal human safety studies, dose-escalation trials, or toxicokinetic studies for carcinine as a standalone supplement have not been published in peer-reviewed sources as of the available literature. Human safety data therefore remain very limited.

8.2 Structural Relationship to Histamine

Carcinine (β-alanyl-histamine) is a selective histamine H3 antagonist, 100–1000-fold selective for H3 over H2 and H1. Because carcinine contains the histamine moiety in its structure, it could theoretically interact with histamine-related pathways, though its selectivity profile distinguishes it substantially from free histamine. Carcinine was active on vertebrate blood pressure at about a thousand times the concentration of histamine, indicating that histamine lost a great extent of its activity when linked with β-alanine. This attenuation of histamine-like activity is a key pharmacological safety feature of the intact dipeptide.

8.3 Carnosinase Resistance (Hydrolysis Stability)

An important pharmacokinetic consideration concerns carcinine's resistance to carnosinase, the enzyme that rapidly hydrolyzes carnosine in human plasma and is a major barrier to oral carnosine supplementation. The resistance to hydrolysis of carnosine mimetic peptide-based compounds with carnosinase has been assessed in a number of biochemical and model systems, with carcinine — whose amino moiety arises from histamine rather than histidine — being less susceptible to carnosinase cleavage than carnosine itself. This feature is the basis for claims of superior bioavailability of carcinine over carnosine in oral supplementation contexts, though rigorous comparative human bioavailability data are not available in the published literature.

8.4 Blood-Retinal Barrier and Tissue Distribution

The amount of carcinine found within the retina after systemic administration is limited, suggesting poor transportation through the blood-retinal barrier, rapid degradation of carcinine within the retina, and/or a rapid reaction with other molecules. This distribution limitation is relevant to both efficacy and pharmacokinetic safety modeling.

8.5 Absence of Regulatory Evaluations

Carcinine has not been reviewed by major regulatory or governmental health bodies — including the U.S. FDA, NIH Office of Dietary Supplements, EFSA, or EMA — with respect to safety standards, maximum tolerated doses, or adverse event characterization for human supplementation. It is listed in the NIH Dietary Supplement Label Database (DSLD) as an ingredient appearing in marketed U.S. products, but no formal safety monograph exists. The overall evidence base is insufficient to characterize its safety profile in populations including pregnant or lactating individuals, those with histamine intolerance or mast cell disorders, or those taking histamine-modulating drugs.

8.6 Potential Pharmacological Interactions

Given carcinine's documented activity as a histamine H3 receptor antagonist, there is a theoretical basis for interactions with other H3-active drugs (e.g., pitolisant, which is an approved H3 antagonist for narcolepsy) or with drugs that modulate histaminergic neurotransmission. This has not been investigated experimentally in any available published study.

9. Overall State of the Evidence

Carcinine is a well-characterized endogenous molecule from a biochemical standpoint, with a clearly defined structure, natural occurrence across multiple phyla, and plausible mechanisms of action rooted in antioxidant chemistry, anti-glycation biology, and histaminergic pharmacology. However, translating these mechanistic findings into clinically verified health benefits faces significant gaps. The clinical validation of carcinine's effects in humans remains limited. While preliminary studies provide a promising outlook, robust clinical trials are necessary to substantiate its efficacy and safety for specific health outcomes. No large-scale, randomized controlled trials have yet conclusively demonstrated the effectiveness of carcinine supplementation in humans.

The published body of evidence rests primarily on in vitro biochemical experiments, cell culture studies, and rodent models. The single human observational study (60 mg/day) is retrospective and anecdotal by the authors' own designation. Carcinine's position as a dietary supplement ingredient therefore rests on mechanistic plausibility and extrapolation from preclinical data, not on a foundation of replicated, rigorously controlled human clinical trials.

References

Health Conditions

Health conditions that Carcinine may help support.

No conditions available.

Body Systems

Body systems that Carcinine may help support.

No body systems available.